Strategic Transactions - Antero Resources (AR) is acquiring HG Energy in the core Marcellus Shale and divesting non-core Utica assets[6, 7] - AR is acquiring HG Energy's upstream business for $2.8 billion plus hedge book, and Antero Midstream (AM) is acquiring HG Energy's midstream business for $1.1 billion[10] - AR is divesting upstream assets in Utica for $800 million, and AM is divesting midstream assets in Utica for $400 million[10] HG Acquisition - The HG Acquisition is expected to add approximately 400 additional locations in the Marcellus Shale core, with 75% being liquids-rich[11, 44] - The acquisition is projected to provide ~$950 million in identified synergies[11] - The acquisition is expected to reduce the cost structure by ~$0.25/Mcfe and increase margins by $0.15 to $0.20 per Mcfe[12] - The acquisition is expected to be 30%+ accretive to operating cash flow, free cash flow, and NAV per share metrics[12, 28] - The acquisition is fully financed and expected to be paid off by 2028 through a combination of AR Free Cash Flow, proceeds from the Utica divestiture, and hedged Free Cash Flow of the acquired assets[13] Pro Forma Outlook - Pro forma production outlook for 2027 is projected to be between 4,400 and 4,500 MMcfe/d[15] Utica Divestiture - The Utica divestiture is expected to generate $800 million in proceeds[10] - The Utica divestiture is expected to have a 2026E Free Cash Flow of ~$55 million[9] Antero Midstream (AM) - AM is acquiring HG Midstream for $1.1 billion and divesting Utica Midstream for $400 million[10, 40] - HG Midstream acquisition is expected to add >400 dedicated locations (75% liquids)[42, 44] - HG Midstream has ~900 MMcf/d of throughput[41]

Business Transformation & Strategy - Ingevity is simplifying its business by exiting Industrial Specialties, Advanced Polymer Technologies (APT), and Road Markings [11, 12] - The company is establishing "New Ingevity" with two core businesses: Performance Materials and Pavement Technologies [12] - New Ingevity will leverage strong cash flow and divestiture proceeds to invest in organic growth, reduce debt, and return capital to shareholders [11] Financial Performance & Outlook - Pro Forma 2025E Revenue for New Ingevity is approximately $900 million [14] - Pro Forma 2025E EBITDA is approximately $335 million, with an EBITDA margin of approximately 37% [14] - The company expects to generate over $200 million of free cash flow per year in 2026 and 2027 [71] - New Ingevity projects 2027E Revenue of $940-980 million and EBITDA of $350-370 million, resulting in an EBITDA Margin of 36-39% [61] - The company aims to maintain a leverage target of 2 to 2.5x [71] Segment Specifics - Performance Materials expects 2025E revenue of approximately $600 million with EBITDA margins exceeding 50% [27] - Pavement Technologies expects 2025E revenue of approximately $300 million with EBITDA margins of 33% [49] Capital Allocation - The company plans to use divestiture proceeds to repurchase approximately $300 million of shares over the next 2 years [75]

Divestiture of the Packaging Sector December 8, 2025 In this presentation, unless otherwise indicated, all financial data are prepared in accordance with International Financial Reporting Standards (IFRS) and the term ''dollars'' as well as the symbol ''$'' designate Canadian dollars. In this document, we also use non-IFRS financial measures for which a complete definition is presented below and for which a reconciliation to financial information in accordance with IFRS is presented in slide 16 "Reconciliat ...

Positive Interim Clinical Data from INLIGHT Trial of WVE-007 in Obesity Investor Presentation December 8, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing ther ...

Aleniglipron Efficacy - In the Phase 2b ACCESS trial, Aleniglipron achieved placebo-adjusted mean weight loss of 82% at 45 mg, 98% at 90 mg, and 113% at 120 mg at 36 weeks[41] - Exploratory ACCESS II study showed placebo-adjusted mean weight loss at 36 weeks of 141% at 120 mg, 144% at 180 mg, and 153% at 240 mg[72] - ACCESS Open Label Extension (OLE) study indicated that weight loss continues to increase in all arms through Week 44, with no evidence of a weight loss plateau[50] Aleniglipron Tolerability and Safety - Phase 2b ACCESS trial showed an overall 104% AE-related treatment discontinuation rate, with GI-related AEs consistent with the GLP-1RA class[41] - In the Exploratory ACCESS II trial, participants who achieved re-randomization experienced no AE-related treatment discontinuations up to the 240 mg dose at week 36[72] - Body Composition study showed improved tolerability with a lower 25 mg starting dose, with no treatment discontinuations due to AEs after a median treatment of approximately 10 weeks[83] - Across all studies with over 500 participants treated up to 44 weeks, there were no events of drug-induced liver injury, off-target safety signals, or QTc prolongation[96] Market Opportunity and Scalability - The overweight and obesity market includes over 800 million people worldwide, with projections of 15 billion people by 2030[14] - The total addressable market for obesity treatments is estimated to be over $100 billion[14] - Oral small molecules like Aleniglipron can scale to meet the needs of the global obesity patient population, offering potential advantages in accessibility and cost compared to injectable peptides[12, 15]

KT-621, Oral STAT6 Degrader, Phase 1b Results 1 Agenda Introduction Justine Koenigsberg Vice President, Investor Relations Revolutionizing Immunology with Oral Medicines Nello Mainolfi, PhD Founder, President and Chief Executive Officer KT-621 BroADen Phase 1b Data Jared Gollob, MD Chief Medical Officer Closing Remarks Nello Mainolfi, PhD Founder, President and Chief Executive Officer Question and Answer Session 2 Forward Looking Statements This presentation contains forward-looking statements within the me ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy December 8, 2025 Forward Looking Statements This presentation discusses an investigational product whose safety and efficacy have not been established. This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regardi ...

Financial Performance & Targets - The company aims for a 12-13% Return on Invested Capital (ROIC) and over $1 billion Free Cash Flow (FCF) by 2028[11] - The company anticipates a 9-10% Trading Profit Compound Annual Growth Rate (CAGR) and 6-7% Organic Revenue CAGR[11] - The company's 12-Point Plan has led to approximately a 300 basis point increase in ROIC, roughly a 14x increase in FCF, and about a 220 basis point increase in Group trading margin[53] Market Position & Strategy (RISE) - The company is well-positioned in attractive markets valued at approximately $50 billion, with a growth rate of 6%[13] - The company's strategy, RISE (Reach more patients, Innovate to enhance the standard of care, Scale through strategic investment, Execute efficiently), aims to elevate the company[57] - The company aims to reach 20 million patients by 2028, an increase of 5 million from the current 15 million[63] Segment Performance & Innovation - In Sports Medicine, the company holds a 25% global market share with a business valued at $1.6 billion in 2024[152] - In Advanced Wound Management, the company holds a 13% global market share in a $13 billion market[14, 255] - The company has launched 78 new products between 2021 and 2025, with over 50% of revenue growth coming from products launched in the last five years[98] Orthopaedics Turnaround - The company is implementing Ortho360 to drive efficiency and profitability in Orthopaedics[83, 383] - The company plans to reduce the number of product families in Orthopaedics to drive greater efficiency[386] - The company is addressing historical overproduction in Orthopaedics, aiming to align supply and demand and improve inventory health[393]

Strategic Rationale - IBM is acquiring Confluent to advance as a software-led hybrid cloud and AI platform company[8] - The acquisition expands IBM's total addressable market (TAM) in the real-time data streaming and event processing market, which is valued at over $100 billion[10, 22] - The deal is expected to be accretive to adjusted EBITDA within the first full year and to free cash flow in year two after closing[11, 28] Confluent Overview - Confluent has approximately 6,500 total customers, with less than 5% having over $1 million in annual recurring revenue (ARR)[14] - Over 40% of Fortune 500 companies have adopted Confluent's technology[14] - Confluent's last twelve months (LTM) revenue exceeds $1 billion[14] Market Drivers - The number of new applications is expected to exceed 1 billion by 2028[21] - 89% of IT leaders consider data streaming platforms critical or important for achieving their data-related goals[21] - Total enterprise AI spending is projected to surpass $800 billion by 2029, more than 3 times the spending in 2024[21] Synergies and Financials - IBM anticipates approximately $500 million in run-rate operational synergies[28] - The transaction has an enterprise value of $11 billion, funded by cash on hand[29] - Confluent's largest shareholders, holding approximately 62% of the voting power, have agreed to vote in favor of the transaction[29, 31]

Z-Rostudirsen Clinical Trial Results - The DELIVER trial of z-rostudirsen in exon 51 DMD met its primary endpoint with a statistically significant increase in dystrophin at 6 months (p<0.0001)[9] - The Registrational Expansion Cohort (REC) replicated a ~7-fold increase in muscle content-adjusted dystrophin from baseline at 6 months with z-rostudirsen 20 mg/kg Q4W (p<0.0001)[32] - Z-Rostudirsen achieved ~10-fold higher level of unadjusted dystrophin relative to the level reported in Phase 3 trial of SoC[37] - The trial showed sustained functional improvement from baseline across multiple clinical endpoints out to 24 months[9] - At 6 months, TTR velocity improved exceeding MCID relative to placebo with nominal p<0.05[42] and 10MWR velocity improved relative to baseline and placebo with nominal p<0.05[45] Safety and Tolerability - Z-rostudirsen has a favorable safety and tolerability profile up to 36 months[59] - 1,062 doses of z-rostudirsen at 20 mg/kg dose level have been administered to date[25] - No participants have persistent related anemia or thrombocytopenia at 20 mg/kg[68] Regulatory and Commercial Strategy - The company plans to submit a BLA for U S Accelerated Approval in Q2 2026[7] - Potential U S launch is anticipated in Q1 2027, assuming FDA grants Priority Review[7] FORCE Platform Validation - The DELIVER trial data validates the potential of the FORCE platform for targeted drug delivery[67]